Champions Oncology AI Stock Analysis
Want to see CSBR full AI Analyst Report?
Champions Oncology (CSBR) AI Stock Analysis
Champions Oncology
(NASDAQ:CSBR)
Overall score is held down primarily by weak financial performance (declining TTM revenue, cash burn, and higher balance-sheet leverage) and a bearish technical setup (below major moving averages with negative MACD). These are partially offset by a constructive earnings-call backdrop showing improving margins and sustained positive adjusted EBITDA, but execution and funding risks remain key.
Champions Oncology Key Performance Indicators (KPIs)
Revenue By SegmentBreaks down revenue by different business segments, highlighting which areas are driving growth and profitability. This can indicate strategic focus and potential areas for expansion or risk.
Revenue is highly concentrated in Pharmacology Services, which produced the recent rebound but still moves in lumpy, project‑timing waves; Other TOS has declined materially since 2024 and Personalized Oncology is effectively immaterial, so true diversification is lacking. A large, irregular TOS license payment in 2025 created a one‑off bump that masks the underlying softness. Investors should view near‑term performance as dependent on repeat pharmacology bookings rather than stable, diversified streams.
The FlyChampions Oncology (CSBR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $64.72M
- Dividend Yield
- ―
- Average Volume (3M)
- 10.26K
- Price to Earnings (P/E)
- -60.0
- Beta (1Y)
- 0.16
- Revenue Growth
- 6.65%
- EPS Growth
- -136.61%
- Country
- US
- Employees
- 214
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Champions Oncology Business Overview & Revenue Model
Company Description
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart...
How the Company Makes Money
Champions Oncology primarily makes money by delivering fee-for-service research and development support to biopharmaceutical companies and other research organizations developing cancer therapeutics. Revenue is generated from contracted services that...
Champions Oncology Earnings Call Summary
The call was strongly positive overall. Management reported approximately 9% revenue growth, significant gross and oncology services margin expansion, the fifth consecutive quarter of positive adjusted EBITDA, stronger data licensing revenue, healthy services demand, and continued Corellia progress. The main cautions were the remaining GAAP net loss, cash usage, lumpy timing of data licensing revenue, higher sales and marketing expense from planned investment, and uncertainty around the timing of a Corellia funding or licensing outcome.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
For fiscal '27, management said it has 3 more quarters to prove out the progress and will keep reporting against it in the same way each time, with a focus on continuing to grow revenue while expanding profitability, maintaining expense discipline, and converting revenue growth into improved profitability; expected conversion percentages remain strong, data license revenue will remain lumpy, and pipeline continues to be robust. Management said it was not going to put a date on any Corellia outcome, but if successful in securing outside funding or a licensing partnership, the investment currently flowing into that business would be redeployed toward other growth initiatives, particularly data and to the bottom line.
Champions Oncology Financial Statement Overview
Summary
Financial statements point to weakening fundamentals: TTM revenue declined 23.6%, profitability reverted to a small net loss (net margin -2.5%), and cash flow turned negative (operating cash flow -$5.6M; free cash flow -$6.1M). Balance-sheet risk is elevated with high leverage versus a small equity base (debt-to-equity 2.54x) and negative ROE (-27.9%). Positives include positive gross margin (33%) and only modest losses versus revenue, but near-term funding/visibility risk remains high.
Income Statement
38NegativeBalance Sheet
34NegativeCash Flow
24Negative| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.66M | 59.42M | 56.94M | 50.16M | 53.87M | 49.11M |
| Gross Profit | 29.91M | 28.52M | 28.55M | 20.75M | 24.34M | 25.48M |
| EBITDA | 447.00K | 448.00K | 6.27M | -5.44M | -3.02M | 2.21M |
| Net Income | -1.14M | -1.18M | 4.70M | -7.28M | -5.33M | 548.00K |
Balance Sheet | ||||||
| Total Assets | 33.29M | 26.99M | 32.34M | 26.13M | 34.31M | 35.38M |
| Cash, Cash Equivalents and Short-Term Investments | 4.36M | 4.87M | 9.79M | 2.62M | 10.12M | 9.01M |
| Total Debt | 10.97M | 4.51M | 6.11M | 7.43M | 8.60M | 9.47M |
| Total Liabilities | 28.83M | 22.92M | 28.57M | 28.04M | 29.68M | 26.28M |
| Stockholders Equity | 3.89M | 3.94M | 3.77M | -1.90M | 4.64M | 9.10M |
Cash Flow | ||||||
| Free Cash Flow | -6.14M | -5.04M | 7.00M | -6.97M | 1.08M | 4.11M |
| Operating Cash Flow | -5.56M | -4.47M | 7.39M | -6.14M | 3.96M | 6.50M |
| Investing Cash Flow | -549.00K | -540.00K | -389.00K | -836.00K | -2.87M | -2.38M |
| Financing Cash Flow | 146.00K | 99.00K | 170.00K | -527.00K | 11.00K | 207.00K |
Champions Oncology Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSBR, the sentiment is Negative. The current price of 4.65 is below the 20-day moving average (MA) of 4.79, below the 50-day MA of 4.91, and below the 200-day MA of 5.64, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 39.72 is Neutral, neither overbought nor oversold. The STOCH value of 17.55 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSBR.
Champions Oncology Risk Analysis
Champions Oncology disclosed 30 risk factors in its most recent earnings report. Champions Oncology reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskChampions Oncology Peers Comparison
Overall Rating
MXCT50Neutral- CSBR48Neutral
LTRN44Neutral
ONCY44Neutral
CRDF42Neutral
BDTX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MXCT | 50Neutral | $113.58M | -4.54 | -17.24% | ― | -0.13% | 38.72% |
| CSBR | 48Neutral | $66.53M | -60.00 | -27.88% | ― | 6.65% | -136.61% |
| LTRN | 44Neutral | $7.18M | -0.29 | -456.35% | ― | ― | 9.68% |
| ONCY | 44Neutral | $52.48M | -1.55 | 1020.21% | ― | ― | 2.05% |
| CRDF | 42Neutral | $59.54M | -1.24 | -103.08% | ― | 11.58% | 32.14% |
| BDTX | 39Underperform | $92.52M | -2.12 | -43.99% | ― | -100.00% | -302.37% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CSBR | Champions Oncology | 4.65 | -2.15 | -31.62% | |
| ONCY | Oncolytics Biotech | 0.37 | -0.67 | -64.23% | |
| CRDF | Cardiff Oncology, Inc. | 0.73 | -1.40 | -65.87% | |
| MXCT | MaxCyte, Inc. | 1.19 | -0.39 | -24.68% | |
| BDTX | Black Diamond Therapeutics, Inc. | 1.52 | -2.49 | -62.09% | |
| LTRN | Lantern Pharma, Inc. | 0.46 | -2.92 | -86.39% |
Champions Oncology Corporate Events
Champions Oncology Stockholders Approve Governance and Incentive Plan
PositiveOn October 14, 2026, Champions Oncology, Inc. held its Annual Meeting of Stockholders, where all seven director nominees were elected to one-year terms and EisnerAmper LLP was ratified as the independent registered public accounting firm for the fisc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026